VIRIDIAN THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 96
- Market Cap
- -
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 284
- Registration Number
- NCT06812325
- Locations
- 🇺🇸
Catalina Eye Care, Tuscon, Arizona, United States
🇺🇸C A Clinical Trial Corp., Cape Coral, Florida, United States
🇺🇸D H Doral Research Center, Doral, Florida, United States
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT06625411
- Locations
- 🇺🇸
C&A Clinical Trials Corp, Cape Coral, Florida, United States
🇺🇸Continental Clinical Research, Miami, Florida, United States
🇺🇸Duke Eye Center, Durham, North Carolina, United States
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT06625398
- Locations
- 🇺🇸
Duke Eye Center, Durham, North Carolina, United States
🇺🇸Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸Alliance Research Institute - Canoga Park, Canoga Park, California, United States
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
- Conditions
- Thyroid eye disease
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Viridian Therapeutics Inc.
- Target Recruit Count
- 155
- Registration Number
- 2023-507563-19-00
- Locations
- 🇳🇱
Stichting Amsterdam UMC, Amsterdam, Netherlands
🇵🇱4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu, Wroclaw, Poland
🇵🇱Santa Sp. z o.o., Lodz, Poland
An Open-label Study for Non-responders of VRDN-001-101 and VRDN-001-301 (OLE)
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: Intervention/Treatment
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT06179875
- Locations
- 🇺🇸
USC Eye Institute, Los Angeles, California, United States
🇺🇸Stanford Byers Eye Institute, Palo Alto, California, United States
🇺🇸University of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Miami, Florida, United States
- Prev
- 1
- 2
- Next